Lung Cancer Trials Ask AI to find trials
CompletedPhase 2NCT00738582
Official study title

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma

Study summary

This research is being done to find out if pemetrexed and cisplatin work better when given together with an experimental drug called MORAb-009 in patients with malignant pleural mesothelioma.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedMORAb-009 (Amatuximab) and Pemetrexed

Plus 1 other study approaches.

Who it may be forMesothelioma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 22, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?28 U.S. locations

Locations may change over time.

Who runs it?Morphotek

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
Morphotek
Interventions being studied
Drug: MORAb-009 (Amatuximab); Drug: Pemetrexed; Drug: Cisplatin
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Mesothelioma→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Primary
  • Confirmed diagnosis of malignant pleural mesothelioma (MPM) with the following characteristics: unresectable disease (or otherwise not a candidate for curative surgery); epithelial type or biphasic (mixed) type with low sarcomatous content.
  • Measurable disease at Screening by computed tomography (CT)(or magnetic resonance imaging \[MRI\]).
  • KPS of greater than or equal to 70% at Screening.
  • Life expectancy of at least 3 months Primary
Reasons someone may not be able to joinExclusion criteria
  • Sarcomatous type of mesothelioma
  • Prior systemic therapy or radiotherapy for MPM; local radiotherapy for symptom control (ie, non-curative intent) is permitted.
  • Confirmed presence of CNS tumor involvement.
  • Evidence of other active malignancy requiring treatment.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of Alabama, BirminghamBirmingham, Alabama
  • University of California, San DiegoLa Jolla, California
  • UCLA Medical Hematology & OncologyLos Angeles, California
  • University of California, San FranciscoSan Francisco, California
  • University of Colorado Cancer CenterAurora, Colorado
  • Christiana Care Health SystemNewark, Delaware
  • Emory University School of MedicineAtlanta, Georgia
  • University of Chicago Medical CenterChicago, Illinois
  • Johns Hopkins University--Sidney Kimmel Comprehensive Cancer CenterBaltimore, Maryland
  • NIH/National Cancer InstituteBethesda, Maryland
  • Columbia University Medical CenterNew York, New York
  • Mary Babb Randolph Cancer CenterMorgantown, West Virginia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 22, 2022. Always confirm current availability with the study team.

View original record ↗